X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inrhythm
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: PhysIQ
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2022
Details:
Based on these positive Phase 2 study results, along with recent interactions with the U.S. Food and Drug Administration (FDA), InCarda plans to conduct a single pivotal Phase 3 trial of InRhythm in patients with recent-onset PAF.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: InRhythm
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2021
Details:
The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: FlecIH
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series C Financing October 21, 2020
Details:
Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: InRhythm
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Deerfield Management
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
